CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 100 enrolled
Drug / intervention
Placebo +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04792645
NCT04792645Phase 2Completed
CompareCT.gov

A Double-Blind, Placebo-Controlled Study of Memantine in Body Focused Repetitive Behaviors

University of Chicago·interventional·Posted Mar 11, 2021·Updated Sep 19, 2024

In Brief

A Phase 2 clinical trial evaluating Placebo and Memantine for Trichotillomania (Hair-Pulling Disorder) and Dermatillomania. Completed, enrolled 100 participants across 1 site.

Detailed Summary

This study is 8 weeks long and involves subjects taking memantine or placebo. If they are randomly assigned to the memantine arm and are eligible to participate in the study, they will begin by taking 10mg once daily of memantine for two weeks, then 20mg for the remaining six weeks. Efficacy and safety measures will be performed at each visit. Participants will be randomized to receive either memantine or placebo on a 1:1 basis. This blinding will be maintained by the IDS pharmacy at the University of Chicago.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsTrichotillomania (Hair-Pulling Disorder), Dermatillomania
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
20222023202420252026
First PostedMar 11, 2021
Enrollment StartJun 15, 2021
Primary CompletionJul 8, 2022
TodayJul 2, 2026
Enrollment to primary: 1.1 yearsPosted 5.3 years ago

Interventions

Placebodrug

Pill that contains no medicine

Memantinedrug

Cognition-enhancing medication